Molecular Basis and Gene Therapies of Cystic Fibrosis

Summary of Genes. Thirty years ago, the gene responsible for cystic fibrosis (CF), a recessive genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene, was identified. This progress has considerably changed our understanding of the pathophysiology of CF an...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2020
Language:English
Physical Description:1 electronic resource (210 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 04071nam-a2200961z--4500
001 993545443304498
005 20231214133526.0
006 m o d
007 cr|mn|---annan
008 202105s2020 xx |||||o ||| 0|eng d
035 |a (CKB)5400000000041976 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/69404 
035 |a (EXLCZ)995400000000041976 
041 0 |a eng 
100 1 |a Engelhardt, John  |4 edt 
245 1 0 |a Molecular Basis and Gene Therapies of Cystic Fibrosis 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2020 
300 |a 1 electronic resource (210 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Summary of Genes. Thirty years ago, the gene responsible for cystic fibrosis (CF), a recessive genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene, was identified. This progress has considerably changed our understanding of the pathophysiology of CF and has paved the way for the development of novel and specific therapies for the disease. The CFTR gene contains 27 exons and is characterized by a frequent three base pair deletion of the p.Phe508del. As a result of collaborative work, today more than 2000 mutations have been reported in the gene, and their impact on protein function is now more evident and useful in designing new strategies to correct the gene defect. The field of gene therapy, as illustrated by Ziying Yan in this book, has worked on identifying an efficient vector system for the delivery of the wild-type CFTR gene to the lung. At the same time, animal models have been developed in mice, rats, rabbits, zebrafish, ferrets, and pigs to establish the efficacity of gene delivery. These animals are also of the utmost importance in testing new molecules as modulators or correctors to improve the CFTR lung function. During the last three decades, the epidemiology of CF has dramatically changed, as today cystic fibrosis is now a chronic adult pulmonary disease. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a cystic fibrosis 
653 |a Staphylococcus aureus 
653 |a superantigen 
653 |a enterotoxin gene cluster 
653 |a MRSA 
653 |a exosomes 
653 |a microvesicles 
653 |a lung 
653 |a primary cells 
653 |a newborn screening 
653 |a trypsinogen 
653 |a CFTR gene 
653 |a next generation sequencing 
653 |a health policy 
653 |a rAAV2/HBoV1 
653 |a baculovirus 
653 |a insect cells 
653 |a lung microbiome 
653 |a metagenomics 
653 |a gut–lung axis 
653 |a Cystic fibrosis 
653 |a CFTR 
653 |a transcriptomics 
653 |a proteostasis 
653 |a small molecules 
653 |a drug development 
653 |a common and new pathogenic variants 
653 |a ethnic Russian population 
653 |a gene therapy 
653 |a cyclophosphamide 
653 |a transient immunosuppression 
653 |a incidence 
653 |a survival 
653 |a genotype-phenotype correlations 
653 |a health policies 
653 |a CFTR modulators 
653 |a human nasal epithelial cells 
653 |a organoids 
653 |a biomarker 
653 |a functional assay 
653 |a pre-clinical in vitro models 
653 |a CFTR-related disorders 
653 |a molecular diagnosis 
653 |a CFTR variants 
653 |a Next Generation Sequencing (NGS) 
653 |a disease liability 
653 |a interpretation 
653 |a penetrance 
653 |a genotype-guided therapy 
653 |a miRNA 
653 |a airway basal cell 
653 |a lentivirus 
776 |z 3-03943-683-X 
776 |z 3-03943-684-8 
700 1 |a Ferec, Claude  |4 edt 
700 1 |a Yan, Ziying  |4 edt 
700 1 |a Engelhardt, John  |4 oth 
700 1 |a Ferec, Claude  |4 oth 
700 1 |a Yan, Ziying  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:56:43 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337965580004498&Force_direct=true  |Z 5337965580004498  |b Available  |8 5337965580004498